News for Transgene SA (TNG.PA)

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Debt Conversion: Approximately EUR33 million converted into equity.Majority Shareholder Ownership: TSGH now owns 69% of Transgene.Financial Visibility: Confirm

Sep 24, 2024 / 04:00PM GMTLucie Larguier - Transgene SA - Chief Financial Officer, Member of the Management Committee Thank you, Heidi, and hello, everyone. I h

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Mar 27, 2024 / 05:00PM GMTUnidentified Company Representative Thank you, Nadia, and hello, everyone. I'm Lucie. I have the pleasure to introduce you today to Dr

Sep 20, 2023 / 04:00PM GMTOperator Hello, and welcome to the Transgene First Half 2023 Financial Results and Business Update Call. Please note, this conference

May 05, 2023 / 02:00PM GMTOperator Hello, and welcome to the Transgene conference call. My name is Ben, and I will be the coordinator for today's call. Please n

Nov 02, 2022 / 05:00PM GMTOperator Good day, and welcome to the positive interim analysis results of Phase II trial evaluating TG4001 plus avelumab conference c

Sep 07, 2022 / 04:00PM GMTOperator Hello, and welcome to the Transgene First Half 2022 Financial Results and Business Update Call. My name is Courtney, and I'll

Nov 23, 2021 / 01:00PM GMTOperator Welcome to the Transgene Conference Call. Please note this conference is being recorded. (Operator Instructions). I will now

Nov 12, 2020 / 11:00PM GMTOperator Hello, and welcome to the presentation of the Phase Ib/II data of TG4001 plus avelumab in HPV16-positive cancers. My name is

Jul 22, 2020 / 05:15PM GMTOperator Hello, and welcome to the Transgene Reports Results from Clinical Study with TG4001. My name is Monique, and I'll be your coo

The eagerly awaited nod offers access to a versatile tool

Key Companies Covered in the Oncolytic Virus Therapy Market Research Report Are Amgen Inc., Shanghai Sunway Biotech Co., Ltd., Oncolys BioPharma Inc., TILT...